Effectiveness and tolerability of zafirlukast for the treatment of asthma in children

Clinical Therapeutics

Volumn 22, Issue 6, 2000, Pages 732-747

  Pearlman, David S ^a   Lampl, Kathy L ^b   Dowling, Paul J Jr ^c   Miller, Christopher J ^d   Bonuccelli, Catherine M ^d  

^a Clin Research Centers of Colorado   (United States)

^b Asthma and Allergy Associates   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; Children; Leukotriene receptor antagonist; Pulmonary function; Zafirlukast.

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; ZAFIRLUKAST;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PROPHYLAXIS; SCHOOL CHILD;

EID: 0033938854     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)90007-9     Document Type: Article

References (21)

1. 1. Smith LJ. Leukotrienes in asthma: The potential therapeutic role of antileukotriene agents. Arch Intern Med. 1996;156:2181-2189.
2. 2. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158:1213-1220.
3. 3. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial. JAMA. 1998;279:1181-1186.
4. 4. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study. Clin Ther. 1997;19:675-690.
5. 5. Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol. 1998;102:935-942.
6. 6. Tashkin DP, Nathan RA, Howland WC, et al. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. J Allergy Clin Immunol. 1999; 103:246-254.
7. 7. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: A randomized controlled trial. JAMA. 1996;275:931-936.
8. 8. Liu MC, Dubé LM, Lancaster J, Zileuton Study Group. Acute and chronic effects of a 5-lipogenase inhibitor in asthma: A 6-month randomized multicenter trial. J Allergy Clin Immunol. 1996;98:859-871.
9. 9. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the diagnosis and management of asthma. Bethesda, Md: National Institutes of Health; 1997. NIH Publication No. 97-4051.
10. 10. Krell RD, Aharony D, Buckner CK, et al. The preclinical pharmacology of ICI 204,219: A peptide leukotriene antagonist. Am Rev Respir Dis. 1990;141:978-987.
11. 4-induced bronchoconstriction in subjects with asthma: A concentration-effect study of ICI 204,219. Clin Pharmacol Ther. 1993; 54:430-436.
12. 12. Zafirlukast prescribing information. Physicians' Desk Reference®. 54th ed. Montvale, NJ: Medical Economics Company; 2000:535-536.
13. 4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE™ Asthma Trialists Group. Am J Respir Crit Care Med. 1994;150: 618-623.
14. 4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr. 1999;134:273-279.
15. 15. Hamill PVV, Drizd TA, Johnson CL, et al. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr. 1979;32:607-629.
16. 16. American Thoracic Society. 1994 update. Standardization of spirometry. Am J Respir Crit Care Med. 1995;152:1107-1136.
17. 17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). E9 Statistical Principles for Clinical Trials. Rockville, Md: US Department of Health and Human Services; 1998.
18. 18. Food and Drug Administration. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th ed. Rockville, Md: US Food and Drug Administration; 1995. Publication PB95-595426INC.
19. 19. Barnes NC, Miller CJ. Effect of leukotriene-receptor antagonist therapy on the risk of asthma exacerbation in patients with mild-to-moderate asthma: An integrated analysis of zafirlukast trials. Thorax. 2000;55: 478-483.
20. 20. Centers for Disease Control and Prevention. Asthma mortality and hospitalization among children and young adults - United States, 1980-1993. MMWR. 1996;45:350-353.
21. 21. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med. 1994;154:1349-1352.